OmniAb, Inc.

SPAC M&A

Capital Markets Advisor, November 2022

Closing of Business Combination with Avista Public Acquisition Corp. II (NASDAQ: AHPA)

The OmniAb (NASDAQ: OABI) discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

More Like This

Aug 2022

Business Combination with Social Capital Suvretta Holdings Corp. I (NASDAQ: DNAA)

Financial Advisor

View Details >
Dec 2021

Business Combination with Thimble Point Acquisition Corp.

Capital Markets Advisor

View Details >
Oct 2021

Business Combination with Mountain Crest Acquisition Corp II

Exclusive Financial and Capital Markets Advisor

View Details >